Mitochondrial Genetics Key to Metastatic Melanoma Immunotherapy Resistance
THURSDAY, June 12, 2025 -- For patients with metastatic melanoma, mitochondrial (MT) haplogroup T (HG-T) is associated with resistance to an anti-programmed cell death protein-1-based immune checkpoint inhibitor (ICI), according to a study published online June 5 in Nature Medicine.
Kelsey R. Monson, Ph.D., from the Perlmutter Cancer Center at NYU Langone Health in New York City, and colleagues examined the association of host MT genetics with ICI efficacy in 1,225 ICI-treated patients with metastatic melanoma.
The researchers discovered and validated significant associations of MT HG-T with resistance to an anti-programmed cell death protein-1-based ICI, both as a single agent and in combination; HG-T was found to be independent of established tumor predictors. A unique nivolumab-resistant baseline peripheral CD8+ T-cell repertoire was exhibited by patients belonging to HG-T compared with other MT haplogroups (pooled odds ratio, 3.46). This was validated in a clinical trial and in an independent standard-of-care ICI cohort.
"Checkpoint immunotherapy has become the mainstay in cancer care in the past decade, especially for those with metastatic melanoma, but until now, it has never been clearly explained why nearly half will not respond to treatment," Monson said in a statement.
Several authors disclosed ties to the biopharmaceutical industry.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Read this next
Cancer Survival Lower in Rural Areas
WEDNESDAY, Oct. 1, 2025 -- Five-year cancer survival rates for each stage of cancer (localized, regional, and distant) is lower in nonmetropolitan areas for Black and White...
Loss of Smell May Linger After COVID-19
WEDNESDAY, Oct. 1, 2025 -- Self-reported change or loss in smell or taste is an accurate signal of verified hyposmia after COVID-19, although there is also a high rate of hyposmia...
Elderly Patients Benefit From Screening Mammography
WEDNESDAY, Oct. 1, 2025 -- Patients with breast cancer diagnosed at 80 years of age or older who received screening mammography present with earlier-stage disease and have better...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.